A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Since 2016 drug developers have spent $23.6bn in-licensing cancer projects, almost half of the sector’s up-front bill.
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Novo moves into amyloidosis not long after Intellia made a splash here.